


Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G₄ deposition: a single-centre retrospective analysis

Xue Jiang,^{1,2} Lan Lan,¹ Qin Zhou,¹ Huijing Wang,¹ Huiping Wang,¹ Jianghua Chen,¹ Fei Han ¹

To cite: Jiang X, Lan L, Zhou Q, *et al.* Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G₄ deposition: a single-centre retrospective analysis. *Lupus Science & Medicine* 2022;9:e000690. doi:10.1136/lupus-2022-000690

Received 3 March 2022
Accepted 9 June 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Nephrology, Zhejiang University; Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province; Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China
²Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China

Correspondence to

Dr Fei Han; hanf8876@zju.edu.cn

ABSTRACT

Objective Renal injury is common in SLE. Immune complex deposition plays an important role in the development of lupus nephritis (LN), while little is known about glomerular IgG₄ deposition in patients with LN. This study aimed to investigate the characteristics and renal outcome of patients with LN with glomerular IgG₄ deposition.

Methods This is a single-centre retrospective study enrolling 89 patients with biopsy-proven LN. Clinicopathological features, treatment responses and renal outcomes were collected and compared between patients with and without glomerular IgG₄ deposition. Renal outcome events include progression of renal dysfunction and end-stage renal disease.

Results Thirty (33.7%) patients had glomerular IgG₄ deposition. Patients with glomerular IgG₄ deposition had lower serum albumin level (25.06±8.61 g/L vs 28.29±6.31 g/L, p=0.05), more class V LN (60.0% vs 35.6%, p=0.03), more positive phospholipase A2 receptor (PLA2R) staining (43.3% vs 18.6%, p=0.01), more IgG₁ deposits (96.7% vs 64.4%, p=0.01) and less C3 deposits (46.7% vs 72.9%, p=0.02) than those without glomerular IgG₄ deposition. They also had better renal survival than those without glomerular IgG₄ deposition (96.7% vs 79.7%, p=0.03). Multivariate Cox regression showed that high serum creatinine level (relative risk (RR)=1.005, 95% CI 1.002 to 1.008, p=0.01) and high Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores (RR=1.078, 95% CI 1.004 to 1.157, p=0.04) independently correlated with poor renal outcome, while glomerular IgG₄ deposition tended to correlate with good renal outcome (RR=5.95, 95% CI 0.759 to 45.97, p=0.09). Further, patients with both glomerular IgG₄ and PLA2R positivity (n=13) had higher levels of serum C3 and C4 and less glomerular C3 deposits compared with those with positive IgG₄ but negative PLA2R in the glomerulus (n=17), and had a tendency of low SLEDAI score (p=0.07).

Conclusions Patients with LN with glomerular IgG₄ deposits may have better renal survival, and patients with LN with simultaneous glomerular IgG₄ and PLA2R deposits may have low disease activity.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ IgG₄ deposition is a potential marker in the differentiation of idiopathic membranous nephropathy, while little is known about the impact of IgG₄ deposition in patients with lupus nephritis.

WHAT THIS STUDY ADDS

⇒ Patients with lupus nephritis with glomerular IgG₄ deposits may have better renal survival.
⇒ Patients with lupus nephritis with simultaneous glomerular IgG₄ and phospholipase A2 receptor deposits may have low disease activity.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

⇒ Elucidating the association of IgG₄ deposition with clinical activity and renal pathological activity in patients with lupus nephritis will help predict the prognosis of the disease.

SLE is a chronic autoimmune and inflammatory disease that affects multiple organs. Nearly 40% of patients with SLE have kidney injury, commonly lupus nephritis (LN). Approximately 10%–30% of patients with LN develop end-stage renal disease (ESRD) within 15 years.^{1,2} Proliferative glomerulonephritis and deposition of various classes of immune complex (IC) in the glomerulus are the main pathological features of LN. IC deposition plays important roles in LN progression.

IgG is a key component of these immune deposits. According to the distinct constant region of its heavy chain, IgG can be classified into four different subclasses. Each subclass has unique biological functions. IgG₁ and IgG₃ contribute to complement activation via binding with high-affinity C1q.^{3,4} IgG₄ is a unique subclass of IgG. It does not bind C1q

and cannot activate complement via the classic pathway because the length and sequence of the amino acids in the hinge region of IgG₄ result in its low binding ability with C1q. There is only weak binding to certain FcγRs, resulting in reduced capacity to activate certain immune effector cells.⁵ IgG₄-containing ICs may activate complement via the mannose-binding lectin pathway, which is reported to be involved in various IC-related glomerulopathies,⁶ most notably IgA nephropathy.⁷ It is accepted that IgG₄ autoantibodies play an important role in the pathogenesis of idiopathic membranous nephropathy (MN). Bannister *et al*⁸ reported nearly 100% IgG₄ deposition in idiopathic MN kidneys, while in secondary MN there is less IgG₄ deposition. In MN secondary to SLE, some studies reported IgG₄ deposition in the glomerulus. Kuroki *et al*⁹ reported that nearly 60% of patients with LN had IgG₄ deposition. Iskandar *et al*¹⁰ reported that most cases of diffuse proliferative LN showed IgG₃ as the major IgG subclass present in glomerular deposits; by contrast, IgG₄ predominated in six of seven cases of MN of unspecified aetiology. Imai *et al*¹¹ reported that three out of four diffuse membranous LN showed glomerular IgG₄ deposition. These patients with subepithelial deposits were similar to those found in patients with MN, showing IgG₄ deposition along the basement membrane. Due to limited number of patients, the impact of glomerular IgG₄ deposition in LN is still controversial. In this study, we examined the distribution of IgG subclass in the glomeruli from LN biopsies and aimed to find the characteristics and renal outcomes of patients with LN with IgG₄ deposition in the glomerulus.

MATERIALS AND METHODS

We retrospectively investigated patients with LN who were hospitalised between September 2015 and April 2017 and were regularly followed up at the Kidney Disease Center of the First Affiliated Hospital, Zhejiang University School of Medicine. All patients fulfilled the American College of Rheumatology 1997 revised criteria for SLE.¹² Renal pathology was obtained from each patient at hospitalisation. Data on clinical symptoms and laboratory findings were collected until the final follow-up.

We collected data including demographic information, clinical symptoms and laboratory examination results. The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score was calculated to evaluate lupus activity. Laboratory results included white cell count (WCC), haemoglobin (HB), platelets (PLT), serum albumin, serum creatinine (SCr), complement C3, complement C4, anti-double-stranded DNA (dsDNA) antibody, urine protein, haematuria and estimated glomerular filtration rate (eGFR).

Renal biopsy tissues were examined by light microscopy, immunofluorescence (IF) and electron microscopy (EM). Histological changes were classified according to the International Society of Nephrology and Renal Pathology Society criteria as follows: class I, minimal mesangial LN; class II, mesangial proliferative LN; class




Figure 1 Immunofluorescence showed staining of IgG subclasses in a patient with class V lupus nephritis.

III, focal LN; class IV, diffuse LN; class V, membranous LN; and class VI, advanced sclerosing LN.¹³ The parameters under light microscopy included glomerular sclerosis and crescents. Glomerular IF staining included IgG and its subclasses IgG₁, IgG₂, IgG₃ and IgG₄, IgM, IgA, C3, C4 and C1q. Their intensity was semiquantitatively scored on a scale from 0 to 3+: 0, absent; 1+, weak; 2+, moderate; and 3+, strong. Typical IF images of IgG subclasses are shown in figure 1. EM was used to observe the deposition sites of ICs in the glomerulus, such as the subcutaneous area, subepithelial area, mesangium and intraglomerular basement membrane (GBM) area.

The interpretation of phospholipase A2 receptor (PLA2R) staining was according to the criteria suggested by Hoxha *et al*.¹⁴ Briefly, it was based on the assessment of two parameters: staining pattern and staining distribution along the glomerular capillary walls. In normal kidney tissue there is very weak expression of PLA2R in the podocytes, which was diagnosed as a negative result in this study. When strong PLA2R staining was presented along the glomerular capillary wall in a fine granular pattern, the result was diagnosed as positive. Typical positive immunohistochemistry staining of PLA2R is shown in figure 2.

Immunosuppressive treatment was collected during follow-up. For response to therapy, complete response (CR) was defined as reduction in proteinuria to <0.5 g/g per 24 hours and stabilisation or improvement in kidney function ($\pm 10\%$ – 15% of baseline); partial response (PR) was defined as reduction in proteinuria by at least 50% and to <3 g/g per 24 hours and stabilisation or improvement in kidney function ($\pm 10\%$ – 15% of baseline). Remission of LN includes CR and PR. Renal outcome events include progression of renal dysfunction, defined as glomerular filtration rate decreasing more than 30% during follow-up, and ESRD, defined as maintaining renal replacement therapy.

Statistical analysis

Statistical analysis was performed by SPSS V.23.0. Descriptive statistics for numerical data are presented as




Figure 2 Immunohistochemistry showing positive PLA2R staining along the glomerular capillary loop in a patient with class V lupus nephritis (arrows point to PLA2R fine granular staining along glomerular capillary loop). PLA2R, phospholipase A2 receptor.

mean±SD or median and IQR, respectively. Differences in numerical data with normal distribution were tested by Student's t-test. Other numerical data and semiquantitative scores were compared by Mann-Whitney U test. Categorical data are presented as counts with percentages (%) and compared by χ^2 test. Renal survival was calculated using Kaplan-Meier analysis with log-rank test. Univariate and multivariate Cox regression were used to analyse the correlation between IgG₄ deposition and renal outcomes. $P < 0.05$ was considered significant.

RESULTS

The analysis included 89 patients, with 16 men and 73 women. According to IgG₄ subclass deposition in the glomerulus, all patients were divided into the IgG₄-positive group (n=30) and the IgG₄-negative group (n=59). The demographic, clinical and histological data at renal biopsy are shown in [table 1](#).

There were no significant differences in age, gender, anti-dsDNA positivity, levels of haematuria, urine protein, SCr, eGFR, WCC, HB, PLT, complement C3 and C4, and IgG, and SLEDAI score between the IgG₄-positive group and the IgG₄-negative group. Patients in the IgG₄-positive group had lower serum albumin level (25.06±8.61 g/L vs 28.29±6.31 g/L, $p=0.05$). For renal pathological changes, there were no differences in the percentage of glomerular sclerosis and crescent between the groups. Patients in the IgG₄-positive group had more class V LN (including III/IV+V, 60.0% vs 35.6%, $p=0.03$), more positive PLA2R staining (43.3% vs 18.6%, $p=0.01$) and more IgG₁ deposits (96.7% vs 64.4%, $p=0.01$), but less C3 deposits (46.7% vs 72.9%, $p=0.02$), compared with those in the IgG₄-negative group. For the deposition sites under EM, two patients in the IgG₄-negative group had no glomerulus and one patient exhibited sclerotic glomeruli under EM, while all the other patients in both groups had multisite deposits under EM (≥ 2 sites). There were 15 (50.0%) patients in the IgG₄-positive group and 30 (53.6%) patients in

the IgG₄-negative group with subendothelial deposits ($p=0.75$).

Patients in the IgG₄-negative group were followed up for 30.78±11.92 months and those in the IgG₄-positive group for 34.00±11.91 months ($p=0.23$). There was no difference in the category of immunosuppressive treatments between the groups. In the IgG₄-negative group, 42 (71.1%) patients achieved CR and 4 (6.8%) patients achieved PR; in the IgG₄-positive group, 17 (56.6%) patients achieved CR and 9 (30.0%) patients achieved PR. Twelve (20.3%) patients in the IgG₄-negative group had renal outcome events more than that in the IgG₄-positive group (one patient, 3.3%) ($p=0.03$). The cumulative renal survival curves by Kaplan-Meier analysis showed patients in the IgG₄-positive group had better renal survival than those in the IgG₄-negative group ([figure 3](#)). Multivariate Cox regression showed that high SCr (RR (relative risk) =1.005, 95% CI 1.002 to 1.008, $p=0.01$) and high SLEDAI score (RR=1.078, 95% CI 1.004 to 1.157, $p=0.04$) independently correlated with poor renal outcome, while glomerular IgG₄ deposition tended to correlate with good renal outcome (RR=5.95, 95% CI 0.759 to 45.97, $p=0.09$).

We further divided patients in the IgG₄-positive group into two subgroups according to PLA2R positivity in the glomerulus. As shown in [table 2](#), there were 13 patients (43.3%) with glomerular PLA2R deposition. Patients in the PLA2R-positive subgroup had higher levels of C3 (73.08±44.68 mg/dL vs 39.82±24.16 mg/dL, $p=0.03$), C4 (16.58±12.19 mg/dL vs 7.41±7.40 mg/dL, $p=0.02$), WCC ($6.56 \pm 4.75 \times 10^9$ /L vs $3.51 \pm 1.56 \times 10^9$ /L, $p=0.04$), HB (114.12±22.56 g/dL(g/L) vs 93.94±22.69 g/dL(g/L), $p=0.02$) and PLT ($212.62 \pm 62.25 \times 10^9$ /L vs $140.12 \pm 48.75 \times 10^9$ /L, $p=0.01$), but less C3 deposits (23.1% vs 64.7%, $p=0.02$), less IgA deposits (30.8% vs 82.4%, $p=0.01$), less IgG₂ deposits (53.8% vs 94.1%, $p=0.01$) and less IgG₃ deposits (53.8% vs 82.4%, $p=0.04$) than those in the PLA2R-negative subgroup. Patients in the PLA2R-positive subgroup had a tendency of lower SLEDAI scores compared with those in the PLA2R-negative subgroup (10.31±4.38 vs 13.29±4.18, $p=0.07$). There were no significant differences in treatment response and renal outcome events between these two subgroups.

DISCUSSION

IgG₄ deposition in the glomerulus is widely reported to be associated with idiopathic MN. In a previous clinical analysis, IgG₄ deposition was also found in different classes of LN, but the deposition rate was significantly lower than that of primary MN.⁹ In our study, 33.7% of patients with LN had glomerular IgG₄ deposition, and among them 60% were diagnosed as class V or combined with class V LN. However, a part of patients with class III/IV LN also had positive IgG₄ staining. In cases of class V LN or combining with class V LN, the IgG₄ positive rate is 46% (18 of 39), while in patients with class III/IV LN the positive rate is 25% (12 of 48). Therefore IgG₄ positivity may not be a good indicator of the presence of an MN pattern.

Table 1 Baseline and follow-up data of patients with lupus nephritis in the IgG₄-negative group and IgG₄-positive group

	IgG ₄ -negative group, n=59	IgG ₄ -positive group, n=30	P value
Age (years)	33.56±12.91	33.30±12.83	0.93
Gender (male/female)	11/48	5/25	0.82
Positive anti-dsDNA antibody, n (%)	31 (54.4)	12 (40.0)	0.20
SLEDAI score	13.78±6.67	12.00±4.45	0.19
IgG (mg/dL)	1203.60±678.27	1257.97±646.85	0.72
IgM (mg/dL)	111.33±94.72	112.62±71.09	0.95
IgA (mg/dL)	266.64±125.09	253.07±120.22	0.63
C3 (mg/dL)	49.90±25.20	53.59±37.36	0.63
C4 (mg/dL)	9.29±9.09	11.21±10.53	0.38
WCC (×10 ⁹ /L)	5.78±2.83	4.83±3.61	0.18
HB (g/dL(g/L))	101.44±21.98	102.93±24.57	0.77
PLT (×10 ⁹ /L)	176.71±72.46	171.53±65.19	0.74
Urine protein (g/g)	3.23 (1.60, 4.75)	3.15 (1.84, 4.96)	0.90
Haematuria	116.00 (26.20, 405.20)	95.30 (39.55, 148.23)	0.47
Serum albumin (g/L)	28.29±6.31	25.06±8.61	0.05
Serum creatinine (µmol/L)	79.00 (59.00, 166.00)	74.00 (59.50, 99.75)	0.34
eGFR (mL/min/1.73 m ²)	80.42±42.13	89.99±35.19	0.26
Pathological classification, n (%)			0.03
II	2 (3.4)	0 (0)	
III/IV	36 (61.0)	12 (40.0)	
V	9 (15.3)	12 (40.0)	
III/IV+V	12 (20.3)	6 (20.0)	
Crescent, n (%)	26 (44.1)	8 (26.7)	0.11
Glomerular sclerosis, n (%)	33 (55.9)	12 (40.0)	0.16
PLA2R staining, n (%)	11 (18.6)	13 (43.3)	0.01
C3 deposition, n (%)	43 (72.9)	14 (46.7)	0.02
C4 deposition, n (%)	24 (40.7)	12 (40)	0.95
C1q deposition, n (%)	36 (61.0)	20 (66.7)	0.60
IgM deposition, n (%)	42 (71.2)	20 (66.7)	0.66
IgA deposition, n (%)	40 (67.8)	19 (63.3)	0.67
IgG deposition, n (%)	39 (66.1)	28 (93.3)	0.01
IgG ₁ deposition	59 (64.4)	29 (96.7)	0.01
IgG ₂ deposition	35 (59.3)	23 (65.2)	0.10
IgG ₃ deposition	29 (49.2)	20 (66.7)	0.12
Multisite deposits under EM (≥2 sites), n (%)	56 (100)	30 (100)	
Subendothelial deposit	30 (53.6)	15 (50.0)	0.75
Immunosuppressive treatment, n (%)			0.83
Steroids+cyclophosphamide	11 (18.6)	5 (16.7)	
Steroids+mycophenolate mofetil	18 (30.5)	7 (23.3)	
Steroids+ciclosporin/tacrolimus	15 (25.4)	8 (26.7)	
Steroids+others	15 (25.4)	10 (33.3)	
Follow-up (months)	30.78±11.92	34.00±11.91	0.23
Treatment response, n (%)			0.01
CR	42 (71.1)	17 (56.6)	
PR	4 (6.8)	9 (30.0)	

Continued

Table 1 Continued

	IgG ₄ -negative group, n=59	IgG ₄ -positive group, n=30	P value
No response	13 (23.0)	4 (13.3)	
Renal outcome event, n (%)	12 (20.3)	1 (3.3)	0.03

CR, complete response; dsDNA, double-stranded DNA; eGFR, estimated glomerular filtration rate; EM, electron microscopy; HB, haemoglobin; PLA2R, phospholipase A2 receptor; PLT, platelet; PR, partial response; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; WCC, white cell count.

However, we found glomerular IgG₄ deposition tended to correlate with good renal outcome in LN. It may predict better renal survival in patients with LN.

IgG₄ cannot induce a predominant immune response and is defined as a non-inflammatory molecule.¹⁵ Human IgG₄ exploits additional properties to modify immune responses, such as dynamic Fab-arm exchange, which results in the formation of bispecific IgG₄ antibodies,^{16 17} and the interaction with the Fc part of other IgG subclass antibodies.^{18–22} Both mechanisms may contribute to human IgG₄-mediated suppression of the hexamer formation by other IgG subclasses. van der Zee *et al*²³ reported that in the blood of beekeepers, the IgG₄ antibody of phospholipase A effectively inhibited complement activation by inhibiting the binding of C1q to IgG₁. Zuo *et al*²⁴ showed that administration of XVII collagen (Col17)-specific human IgG₄ autoantibodies (from auto-immune patients with bullous pemphigoid skin disease) to humanised Col17 mice inhibited the complement activation and disease development by interfering with other IgG subclasses. Another study showed that IgG₄ binds to the Fc portions of IgG₁, IgG₂ and IgG₃ and blocks the Fc-mediated effector functions of IgG₁ and IgG₃ complexes and may assist in the clearance of ICs by forming larger complexes that are more effectively cleared, resulting in termination of the inflammatory process.¹⁶ In patients with SLE and in lupus-prone MRL-lpr mice, Pan *et al*²⁵ revealed that IgG₄ autoantibody

(antinuclear IgG₄) attenuates SLE disease progression and suppresses complement consumption and inflammatory cytokine production by competitively binding to autoantigens to form non-pathogenic ICs that result from the low affinity of IgG₄ for both the Fcγ receptor and the C1 complement molecule. Pan *et al*²⁶ also reported that serum antinuclear IgG₄ in patients with SLE was positively correlated with C3 and negatively correlated with 24-hour urinary protein. The ratio of the deposition score for IgG₄ (IgG₁+IgG₂+IgG₃+IgG₄) was negatively correlated with the score for C1q and C3 deposition in LN, which means IgG₄ autoantibody may dampen the inflammatory response in SLE and thus may provide a novel therapeutic target for SLE.²⁶

PLA2R, a transmembrane receptor in glomerular podocytes, is the major target antigen in idiopathic MN. Anti-PLA2R antibodies frequently consist of the IgG₄ subtype, and glomerular capillary IgG₄ deposition is a potential marker in the differentiation of primary MN from secondary MN.²⁷ In idiopathic MN, most patients have IgG₄ and PLA2R deposition in the glomerulus at the same time. A study by Kaya *et al*²⁷ reported that 46.9% of patients with idiopathic MN had IgG₄ and PLA2R dual-positive staining in the kidney. Another study showed that 88.3% of patients with idiopathic MN simultaneously had PLA2R and IgG₄ deposition in the glomeruli. Patients with MN with positive PLA2R expression may respond to glucocorticoid and/or immunosuppressant therapy,²⁸ while Qin *et al*²⁹ reported that sustained PLA2R deposits in kidney tissue correlated with low spontaneous remission, low response to immunosuppressants or increased disease relapse. Membranous LN usually presents anti-PLA2R-negative, although cases of PLA2R-positive membranous LN have been reported,^{30 31} while the relationship between the PLA2R and IgG₄ staining patterns and treatment response of patients with LN was not mentioned in the previous study.

In the present study, we found that 14.6% of patients with LN had both IgG₄ and PLA2R staining, and among these patients 76.9% were diagnosed as class V LN. It may be difficult to differentiate class V LN and primary MN in renal pathology. In our study, 21 patients were diagnosed as class V LN. All of them had IC deposits in multiple sites of glomerulus. Among them, 2 (9.5%) patients had subendothelial, subepithelial, mesangial and intra-GBM deposits; 16 (76.2%) patients had subepithelial, mesangial and intra-GBM deposits; 3 (14.3%)




Figure 3 Cumulative renal survival rates by Kaplan-Meier analysis. Patients in the IgG₄-positive group had better renal survival than patients in the IgG₄-negative group (p=0.03).

Table 2 Baseline and follow-up data of patients with lupus nephritis with IgG₄ deposits in the PLA2R-negative subgroup and PLA2R-positive subgroup

	PLA2R-negative subgroup, n=17	PLA2R-positive subgroup, n=13	P value
Age (years)	35.76±12.63	30.08±12.86	0.24
Gender (male/female)	3/14	2/11	0.87
Positive anti-dsDNA antibody, n (%)	9 (52.9)	3 (23.1)	0.10
SLEDAI score	13.29±4.18	10.31±4.38	0.07
IgG (mg/dL)	1424.71±731.89	1021.75±426.74	0.09
IgM (mg/dL)	104.59±68.59	124.00±76.04	0.49
IgA (mg/dL)	282.29±121.33	211.67±110.40	0.12
C3 (mg/dL)	39.82±24.16	73.08±44.68	0.03
C4 (mg/dL)	7.41±7.40	16.58±12.19	0.02
WCC (×10 ⁹ /L)	3.51±1.56	6.56±4.75	0.04
HB (g/dL)(g/L)	93.94±22.69	114.12±22.56	0.02
PLT (×10 ⁹ /L)	140.12±48.75	212.62±62.25	0.01
Urine protein (g/g)	3.40 (2.30, 4.44)	2.54 (0.53, 6.64)	0.62
Haematuria	119.90 (60.90, 287.55)	57.20 (23.15, 114.35)	0.79
Serum albumin (g/L)	23.94±7.12	26.54±10.39	0.45
Serum creatinine (µmol/L)	75.00 (65.00, 104.00)	61.00 (53.00, 82.00)	0.94
eGFR (mL/min/1.73 m ²)	79.94±30.95	103.15±37.21	0.07
Pathological classification, n (%)			0.09
II	0 (0)	0 (0)	
III/IV	9 (52.9)	3 (23.1)	
V	4 (23.5)	8 (61.5)	
III/IV+V	4 (23.5)	2 (15.4)	
Crescent, n (%)	5 (29.4)	3 (23.1)	0.69
Glomerular sclerosis, n (%)	7 (41.2)	5 (38.5)	0.88
C3 deposition, n (%)	11 (64.7)	3 (23.1)	0.02
C4 deposition, n (%)	9 (52.9)	3 (23.1)	0.09
C1q deposition, n (%)	12 (70.6)	7 (52.8)	0.60
IgM deposition, n (%)	13 (76.5)	7 (53.8)	0.19
IgA deposition, n (%)	14 (82.4)	4 (30.8)	0.01
IgG deposition, n (%)	16 (94.1)	12 (92.3)	0.84
IgG ₁ deposition	17 (100)	12 (92.3)	0.25
IgG ₂ deposition	16 (94.1)	7 (53.8)	0.01
IgG ₃ deposition	14 (82.4)	7 (53.8)	0.04
Multisite deposits under EM (≥2 sites), n (%)	17 (100)	13 (100)	
Subendothelial deposit	10 (58.8)	5 (38.5)	0.27
Immunosuppressive treatment, n (%)			0.67
Steroids+cyclophosphamide	4 (23.5)	1 (7.7)	
Steroids+mycophenolate mofetil	4 (23.5)	3 (23.1)	
Steroids+ciclosporin/tacrolimus	4 (23.5)	4 (30.8)	
Steroids+others	5 (29.4)	5 (38.5)	
Follow-up (months)	33.56±12.03	34.54±12.21	0.57
Treatment response, n (%)			0.59
CR	11 (64.7)	6 (46.2)	

Continued

Table 2 Continued

	PLA2R-negative subgroup, n=17	PLA2R-positive subgroup, n=13	P value
PR	4 (23.5)	5 (41.7)	
No response	2 (11.8)	2 (16.7)	
Renal outcome events, n (%)	1 (5.9%)	0 (0%)	0.37

CR, complete response; dsDNA, double-stranded DNA; eGFR, estimated glomerular filtration rate; EM, electron microscopy; HB, haemoglobin; PLA2R, phospholipase A2 receptor; PLT, platelet; PR, partial response; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; WCC, white cell count.

patients had subendothelial, mesangial and intro-GBM deposits; and 2 (9.5%) patients had subepithelial and intra-GBM deposits. In view of the above pathological features, we diagnosed these patients as class V LN rather than primary MN, even though a part of them had PLA2R deposition. Such cases were also reported by Garcia-Vives *et al.*³² where circulating anti-PLA2R antibodies were detected in 7 of 37 patients with membranous LN (18.9%), of whom 5 also had positive glomerular immunohistochemistry staining for PLA2R. We further found that patients with LN with both PLA2R and IgG₄ deposits in the glomerulus had higher levels of serum C3 and C4 and a tendency of lower SLEDAI scores than those with positive IgG₄ but negative PLA2R staining. Also, for pathological changes, the glomerular deposits of C3, IgA, IgG₂ and IgG₃ were lower in patients with LN with both PLA2R and IgG₄ deposits. These findings showed that patients with LN with IgG₄ and PLA2R dual-positive staining in the glomerulus might have low disease activity.

There are several limitations to this study. First, this is a retrospective study with a relatively small size of cases. Second, for the relatively short follow-up period, we need longer follow-up time to determine the effect of IgG₄ deposition on long-term prognosis of LN. Third, because we only included cases at our centre, our pathological techniques and diagnostic inertia may cause bias.

In conclusion, patients with LN with glomerular IgG₄ deposits may have better renal survival, and patients with LN with simultaneous glomerular IgG₄ and PLA2R deposits may have low disease activity.

Acknowledgements We thank all clinicians at the Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, for their efforts in this study.

Contributors All authors were involved in analysing and interpreting the data, drafting the article and revising it critically for important intellectual content, and all read and approved the final version to be published. FH is the guarantor.

Funding This is supported by the National Natural Science Foundation of China (no: 82104586; to XJ) and the Primary Research and Development Plan of Zhejiang Province (2020C03034; to FH).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval This study involves human participants and the study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University School of Medicine (no: 2020571). Informed consent was not obtained

from the patients of this study, as approved by the Ethics Committee. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Fei Han <http://orcid.org/0000-0001-5363-7556>

REFERENCES

- Parikh SV, Almani S, Brodsky S, *et al.* Update on lupus nephritis: core curriculum 2020. *Am J Kidney Dis* 2020;76:265–81.
- Costenbader KH, Desai A, Alarcón GS, *et al.* Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. *Arthritis Rheum* 2011;63:1681–8.
- Heijnen IA, van de Winkel JG. Human IgG Fc receptors. *Int Rev Immunol* 1997;16:29–55.
- Nirula A, Glaser SM, Kalled SL, *et al.* What is IgG4? A review of the biology of a unique immunoglobulin subtype. *Curr Opin Rheumatol* 2011;23:119–24.
- Aalberse RC, Stapel SO, Schuurman J, *et al.* Immunoglobulin G4: an odd antibody. *Clin Exp Allergy* 2009;39:469–77.
- Lhotta K, Würzner R, König P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. *Nephrol Dial Transplant* 1999;14:881–6.
- Liu L-L, Liu N, Chen Y, *et al.* Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy. *Clin Exp Immunol* 2013;174:152–60.
- Bannister KM, Howarth GS, Clarkson AR, *et al.* Glomerular IgG subclass distribution in human glomerulonephritis. *Clin Nephrol* 1983;19:161–5.
- Kuroki A, Shibata T, Honda H, *et al.* Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. *Intern Med* 2002;41:936–42.
- Iskandar SS, Falk RJ, Jennette JC. Clinical and pathologic features of fibrillary glomerulonephritis. *Kidney Int* 1992;42:1401–7.
- Imai H, Hamai K, Komatsuda A, *et al.* IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. *Kidney Int* 1997;51:270–6.
- Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:40:1725.
- Weening JJ, D'Agati VD, Schwartz MM, *et al.* The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney Int* 2004;65:521–30.
- Hoxha E, Kneißler U, Stege G, *et al.* Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. *Kidney Int* 2012;82:797–804.
- Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. *Clin Exp Immunol* 2015;181:191–206.

- 16 van der Neut Kofschoten M, Schuurman J, Losen M, *et al.* Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. *Science* 2007;317:1554–7.
- 17 Labrijn AF, Buijsse AO, van den Bremer ETJ, *et al.* Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. *Nat Biotechnol* 2009;27:767–71.
- 18 Cohen PL, Cheek RL, Hadler JA, *et al.* The subclass distribution of human IgG rheumatoid factor. *J Immunol* 1987;139:1466–71.
- 19 Zack DJ, Stempniak M, Wong AL, *et al.* Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis. *J Immunol* 1995;155:5057–63.
- 20 Ito T, Kitahara K, Umemura T, *et al.* A novel heterophilic antibody interaction involves IgG4. *Scand J Immunol* 2010;71:109–14.
- 21 Rispens T, Ooievaar-De Heer P, Vermeulen E, *et al.* Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. *J Immunol* 2009;182:4275–81.
- 22 Rispens T, Meesters J, den Bleker TH, *et al.* Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. *Mol Immunol* 2013;53:35–42.
- 23 van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. *Clin Exp Immunol* 1986;64:415–22.
- 24 Zuo Y, Evangelista F, Culton D, *et al.* IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid. *J Autoimmun* 2016;73:111–9.
- 25 Pan Q, Xiao H, Shi L, *et al.* IgG4 autoantibodies attenuate systemic lupus erythematosus progression by suppressing complement consumption and inflammatory cytokine production. *Front Immunol* 2020;11:1047.
- 26 Pan Q, Guo L, Wu J, *et al.* Association between IgG4 autoantibody and complement abnormalities in systemic lupus erythematosus. *Mediators Inflamm* 2016;2016:1–7.
- 27 Kaya B, Paydas S, Balal M, *et al.* Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings. *Int J Clin Pract* 2021;75:e13855.
- 28 Dong H-R, Wang Y-Y, Cheng X-H, *et al.* Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in Chinese patients with membranous nephropathy. *PLoS One* 2016;11:e0156263.
- 29 Qin H-Z, Zhang M-C, Le W-B, *et al.* Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy. *J Am Soc Nephrol* 2016;27:3195–203.
- 30 Beck LH, Bonegio RGB, Lambeau G, *et al.* M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med* 2009;361:11–21.
- 31 Gunnarsson I, Schlumberger W, Rönnelid J. Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis. *Am J Kidney Dis* 2012;59:585–6.
- 32 Garcia-Vives E, Solé C, Moliné T, *et al.* Antibodies to M-type phospholipase A₂ receptor (PLA₂R) in membranous lupus nephritis. *Lupus* 2019;28:396–405.